MEET OUR TEAM

Please meet the people behind our company, led by Tom Wiggans, with additional industry veterans from Connetics, Peplin, Stiefel and Gilead.

TECHNOLOGY SPOTLIGHT

Cimzia®, our lead product candidate, is a PEGylated, humanized antigen-binding mAb fragment TNF inhibitor in development for the treatment of moderate-to-severe plaque psoriasis.

Dermira Reports Third Quarter 2014 Financial Results and Provides Corporate Update

Dermira Reports Third Quarter 2014 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) — Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today reported financial results for the quarter ended September 30, 2014. “With the clinical… View Article

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients.